Was I Right To Big Up Barclays PLC Last Year?

Harvey Jones is happy to report that Barclays PLC (LON: BARC) has performed well since he tipped it last year, but did it perform well enough to tip it again?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

In spring last year, I was full of the joys of the buying opportunity that was Barclays (LSE: BARC) (NYSE: BCS.US).

As its share price plunged to 232p in March, I loudly proclaimed that “Barclays has slipped even deeper into buy territory”.

I wrote a string of articles on the stock at the time, claiming that “the worse Barclays gets, the more I want to buy it”.

Was I right to stick my neck out?

Barclays Bitten

One year ago, Barclays was having a tough time of it. Profits at its investment banking arm had collapsed, as regulatory demands were squeezing it out of Wall Street.

In Europe, it was facing a costly financial transactions tax. At home, chief executive Anthony Jenkins had stumbled into a major row over fat banker bonuses.

His costly overhaul Project Transform had yet to bear fruit, and the public still loathed Barclays, forgetting that it didn’t need a taxpayer bail out in the financial crisis.

Worse, its share price had just hit an 18-month low, and was a depressing 5% lower than five years earlier.

On The Contrary

All of which made Barclays look like a great contrarian opportunity to me. I concluded: “You could wait for it to get cheaper, but frankly, it looks like a buy today.”

And it did get cheaper, before a moderate recovery finally kicked in. Today, Barclays is trading at 262p.

That’s a rise of 13% I wrote those words at the end of last March, against under 5% on the FTSE 100.

Most of the action came in the last six months, when Barclays outperformed the other UK banks, and most European banks as well.

It now trades at 0.8 times book value, up from 0.6 times before.

Which is good, although hardly the stuff that makes fortunes.

Get With The Programme

Barclays, like the banking sector generally, remains a stock in recovery. It keeps lapsing into bad habits, with the seemingly endless stream of mis-selling and rate-rigging scandals.

Its investment banking arm continues to wither, stunted by regulation, and in urgent need of radical surgery that management seem reluctant to perform.

At 10.3%, at least its capital position is stronger. And the yield is returning to respectability: currently 2.5%, but forecast to hit 3.7% later this year, and 4.7% at the end of 2016.

I wasn’t wrong to big up Barclays last year. And if you want exposure to UK banks it is trading at an undemanding valuation. I reckon it is still a buy today.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Harvey Jones has no position in any shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Stacks of coins
Investing Articles

1 penny stock mistake to avoid in 2025

Ben McPoland explores a rookie error common to penny stock investing, and also highlights a 19p small-cap that looks like…

Read more »

Warren Buffett at a Berkshire Hathaway AGM
Investing Articles

What can Warren Buffett teach an investor with £1,000?

Although Warren Buffett’s a billionaire, his investing lessons can be applied to far more modest portfolios. Our writer explains some…

Read more »

Light bulb with growing tree.
Investing Articles

Down 43%, could the ITM share price start rising again in 2025?

After news of the latest sales deal being inked, our writer revisits the ITM share price and considers if the…

Read more »

Runner standing at the starting point with 2025 year for starting in new year 2025 to achieve business planing and success concept.
Investing Articles

Is 2024’s biggest FTSE faller now the best share to buy for 2025?

Harvey Jones thought this FTSE 100 growth stock was the best share to buy for 2024, but was wrong. Yet…

Read more »

New year resolutions 2025 on desk. 2025 resolutions list with notebook, coffee cup on table.
Investing Articles

Legal & General has huge passive income potential with a forecast yield of almost 10% in 2025!

Harvey Jones got a fabulous rate of passive income from this top FTSE 100 dividend stock in 2024, and believes…

Read more »

Investing Articles

This stock market dip is my chance to buy cheap FTSE shares for 2025!

Harvey Jones was looking forward to a Santa Rally in December, but it looks like we're not going to get…

Read more »

Investing Articles

Analysts are saying the AstraZeneca share price looks cheap despite China turmoil

The AstraZeneca share price could be considerably undervalued according to analysts. Dr James Fox takes a closer look at the…

Read more »

Pink 3D image of the numbers '2025' growing in size
Investing Articles

1 FTSE 100 stock I expect to outperform in 2025

Can the integration of its big acquisition from 2022 finally lead Rentokil Initial to outperform the FTSE 100 next year?…

Read more »